+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
530057 VIVANZA

Vivanza Biosciences Share Price

 

 

Vivanza Biosciences live price: ₹1.85. It opened at ₹2 vs previous close ₹2; intraday high/low: ₹2/₹2. The 50 & 200 DMA stand at ₹1.89/₹2.07.

Vivanza Biosciences Performance

  • Today's Low
  • ₹2
  • Today's High
  • ₹2
  • 52 Week Low
  • ₹2
  • 52 Week High
  • ₹3
  • Open Price₹2
  • Previous Close₹2
  • Volume5,262
  • 50 DMA₹1.89
  • 100 DMA₹1.93
  • 200 DMA₹2.07

Vivanza Biosciences Chart

Investment Returns

  • Over 1 Month + 8.82%
  • Over 3 Month -9.31%
  • Over 6 Month -17.41%
  • Over 1 Year -12.32%

Smart Investing Starts Here Start SIP with Vivanza Biosciences for Steady Growth!

Invest Now

Vivanza Biosciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 18.8
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 7
  • P/B Ratio
  • 1.7
  • Average True Range
  • 0.11
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.02
  • RSI
  • 48.49
  • MFI
  • 46.9

Vivanza Biosciences Financials

Vivanza Biosciences Technicals

EMA & SMA

Current Price
₹1.85
-0.03 (-1.6%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹1.90
  • 50 Day
  • ₹1.90
  • 100 Day
  • ₹1.90
  • 200 Day
  • ₹2.10

Resistance and Support

1.86 Pivot Speed
  • R3 1.88
  • R2 1.88
  • R1 1.86
  • S1 1.84
  • S2 1.84
  • S3 1.82

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vivanza Biosciences has an operating revenue of Rs. 115.91 Cr. on a trailing 12-month basis. An annual revenue growth of 1451% is outstanding, Pre-tax margin of 0% needs improvement, ROE of 9% is fair but needs improvement. The company has a reasonable debt to equity of 20%, which signals a healthy balance sheet. From an O'Neil Methodology perspective, the stock has an EPS Rank of 53 which is a POOR score indicating inconsistency in earnings, a RS Rating of 36 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 48 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Vivanza Biosciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-06-18 Others Inter-alia, to consider 1. Approve appointment of Mr. Hemant Amrish Parikh as a Non-Executive Non-Independent Director. 2. Approve the transfer of certain unverified shares. 3. Other business matters. split from Rs. 10/- to Re. 1/-.
2026-05-07 Audited Results (Revised) split from Rs. 10/- to Re. 1/-.
2026-02-12 Quarterly Results
2025-11-11 Quarterly Results
2025-09-01 Others Inter-alia, to consider 1. Appoint Mr. Chintan K. Patel, Practicing Company Secretary as a Scrutinizer & Secretarial Auditors of the Company. 2. Draft notice of 43rd AGM. 3. Other business matters. split from Rs. 10/- to Re. 1/-.
Date Purpose Remarks
2023-03-24 Split Rs.0.00 split from Rs. 10/- to Re. 1/-.

Vivanza Biosciences Shareholding Pattern

20.02%
0%
73.34%
6.64%

Vivanza Biosciences FAQs

Vivanza Biosciences share price is ₹1 As on 15 July, 2026 | 01:49

The Market Cap of Vivanza Biosciences is ₹7.4 Cr As on 15 July, 2026 | 01:49

The P/E ratio of Vivanza Biosciences is 18.8 As on 15 July, 2026 | 01:49

The PB ratio of Vivanza Biosciences is 1.7 As on 15 July, 2026 | 01:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23